DBV Technologies

Regulatory Filings • May 5, 2015

Press Release Bagneux, France, May 5, 2015

DBV Technologies to Present at Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinicalstage specialty biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following upcoming investor conferences:

• Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, at 8:40 am ET in Las Vegas, NV.
• 2015 UBS Global Healthcare Conference on Wednesday, May 20, 2015 at 12:00 pm ET in New York, NY.

A live audio webcast of these presentations will be available on the Investor Relations section of the company's website, http://www.dbv-technologies.com/en/investor-relations. A replay of the presentations will be available on DBV's website within 48 hours after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.

DBV Technologies Contacts

Nathalie Donne Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 nathalie.donne@dbv-technologies.com

DBV Technologies Media Contacts

Marion Janic Rooney & Associates Tél. : +1-212-223-4017 mjanic@rooneyco.com Susanna Mesa VP Finance, US Investor Relations & Strategy Tél. : +1 917-346-3447 susanna.mesa@dbv-technologies.com